Fernando Valenzuela

Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial

H. Bachelez, P.C.M. van de Kerkhof, Robert Strohal et al. · The Lancet · 2015 · 388 citations · Full text

Autoimmune Disease, Clinical Trials, Inflammatory Marker +7

Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council

Bruce Strober, Caitriona Ryan, Peter van de Kerkhof et al. · Journal of the American Academy of Dermatology · 2019 · 226 citations · Full text

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt et al. · The Lancet · 2022 · 211 citations

Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis, Multicentre Phase 3 +6

Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study

Satveer K. Mahil, Nick Dand, K.J. Mason et al. · Journal of Allergy and Clinical Immunology · 2020 · 158 citations · Full text

Adverse Covid-19 Outcomes, Global Health, Covid-19 Pandemic +9

Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial

Andrew Blauvelt, Jonathan I. Silverberg, Charles Lynde et al. · Journal of the American Academy of Dermatology · 2021 · 140 citations · Full text